Valvuloplasty as Alternative to Toupet Fundoplication for GERD
NCT ID: NCT02625077
Last Updated: 2017-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2016-01-31
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial Comparing Open and Laparoscopic Nissen Fundoplication in Children
NCT00382850
Laparoscopic Total vs Partial Fundoplication in Patients With Atypical Symptoms of Gastroesophageal Reflux Disease
NCT05647668
Necessity of Esophageal Dissection During Laparoscopic Fundoplication
NCT00287612
Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia.
NCT04436159
Applying Long-term Follow-up to Improve Patient Selection in Laparoscopic Anti-reflux Surgery
NCT03959020
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Block randomization will be used to ensure an equal number in each treatment arm. Block randomization works by randomizing participants within blocks such that an equal number are assigned to each treatment. To reduce selection bias by predictability of the treatment allocation, random block sizes are used. Also the investigator is kept blind to the size of each block. A computer is used to generate 15 blocks for each participating center with random block sizes of 4, 8 and 12. Allocation proceeds by randomly selecting one of the orderings and assigning the next block of participants to study groups according to the specified sequence.
Patients will be included during a two-year period and followed for a minimum of one year. When a patient is referred to a participating surgeon for antireflux surgery, he or she will receive study information to give them sufficient time for consideration. The surgeon will ensure all required pre-operative diagnostic tests are performed and that the indication for surgery is valid. During a follow-up visit, the surgeon ascertains that the patient complies with all inclusion criteria and does not meet any of the exclusion criteria. Study participation will be discussed and after informed consent is obtained, the patient will be included in the trial.
After inclusion, the patient is immediately randomized but treatment allocation is not yet shared with the surgeon. The patient will receive validated questionnaires to record the pattern of symptoms, quality of life, medication and medical care usage. Data from the pre-operative tests will be recorded.
On the day of surgery, the surgeon will be able to see treatment allocation and after performing the appropriate surgical procedure, records the course and specifics of the surgical procedure. Patients will receive a diary to record their meals and symptoms.
Follow-up in the outpatient clinic will take place at the surgeon's discretion. At fixed moments: 3, 6 and 12 months after surgery, the patients will once more receive validated questionnaires. Also at about three months, a follow-up manometry and 24-hour pH and/or impedance monitoring will be performed.
A power analysis was performed to calculate the sample size. Our primary aim was to compare the effect of both surgical procedures. Based upon the current medical literature, the objective/subjective success rate for the laparoscopic Toupet fundoplication is around 88%. Pilot data from a retrospective cohort of patients that underwent valvuloplasty report a subjective success rate of 96%. Our hypothesis was that the gastroesophageal valvuloplasty is not inferior to the Toupet fundoplication when comparing its effects on acid control.
To prove non-inferiority of the valvuloplasty regarding acid reflux control, using a non-inferiority limit of 5%, 73 patients are required in each group. In all power calculations, a significance of 5% and power of 90% was used.
To accommodate for a loss to follow-up of up to 10 percent, a total sample size of 160 was chosen.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Laparoscopic valvuloplasty
Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.
Laparoscopic gastroesophageal valvuloplasty
Laparoscopic Toupet fundoplication
Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.
Laparoscopic Toupet fundoplication
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laparoscopic gastroesophageal valvuloplasty
Laparoscopic Toupet fundoplication
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18
* Written informed consent for study participation
Exclusion Criteria
* Hiatal hernia \>3cm
* Achalasia
* Previous gastric surgery
* Previous esophageal surgery
* Inability to understand the Dutch language
* Inability to understand and/or fill in the questionnaires
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meander Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
R.C. Tolboom, MD
Project Leader
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Werner A Draaisma, MD, PhD
Role: STUDY_DIRECTOR
Meander Medical Center
Ivo AM Broeders, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Meander Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Meander Medical Center
Amersfoort, Utrecht, Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Meander Medical Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL52398.100.15
Identifier Type: REGISTRY
Identifier Source: secondary_id
CHI-UPPERGI-VANTAGE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.